drug
ixekizumab
Marketedupdated 3mo agoby Eli Lilly and Co
Approvedcommunity read0 votes
all catalysts(0)
nothing on the calendar yet
Trials studying ixekizumab
- phase3A Study of Switching to Picankibart in Chinese Patients With Plaque Psoriasis With an Inadequate Response to Interleukin-17 Monoclonal Antibody Therapy
- phase3A Study of Ixekizumab (LY2439821) in Children With Juvenile Idiopathic Arthritis Categories of Enthesitis-related Arthritis (Including Juvenile Onset Ankylosing Spondylitis) and Juvenile Psoriatic Arthritis
- N/ACombination of Biologic and Anti-obesity Therapies in Psoriatic Arthritis
- phase3Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Psoriatic Arthritis and Obesity or Overweight
- phase3Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Moderate-to-Severe Plaque Psoriasis and Obesity or Overweight
- phase1Study to Compare Pharmacokinetics and Safety of CT-P52 and US-licensed Taltz in Healthy Subjects
- phase4A Study of Ixekizumab (LY2439821) in Participants Aged ≥18 Years With Moderate-to-Severe Plaque or Active Psoriatic Arthritis in India
- phase4COVID-19 VaccinE Response in Rheumatology Patients
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 55m ago
Found something off?
comments(0)
5-min edit window · permanent after that